Lineage Q2 2024 Earnings Report
Key Takeaways
Lineage Cell Therapeutics reported a net loss of $5.8 million, or $0.03 per share, for the three months ended June 30, 2024. Total revenues for the quarter were $1.4 million. Cash, cash equivalents, and marketable securities totaled $38.5 million as of June 30, 2024, expected to support planned operations into Q4 2025.
24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech
Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program
OPC1 Clinical Study Start Up Preparations Ongoing
Lineage
Lineage
Forward Guidance
Cash, cash equivalents, and marketable securities of $38.5 million as of June 30, 2024 is expected to support planned operations into Q4 2025.